Wiley Bros. Aintree Capital, LLC Gilead Sciences, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $14.9 Billion
- Q3 2025
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 303,379 shares of GILD stock, worth $37.6 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
303,379
Previous 273,590
10.89%
Holding current value
$37.6 Million
Previous $30.3 Million
11.02%
% of portfolio
0.23%
Previous 0.24%
Shares
9 transactions
Others Institutions Holding GILD
# of Institutions
2,406Shares Held
1.01BCall Options Held
8.58MPut Options Held
7.35M-
Vanguard Group Inc Valley Forge, PA121MShares$15 Billion0.23% of portfolio
-
Black Rock Inc. New York, NY121MShares$15 Billion0.19% of portfolio
-
State Street Corp Boston, MA59.1MShares$7.33 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA45.2MShares$5.61 Billion0.72% of portfolio
-
Dodge & Cox San Francisco, CA30.1MShares$3.74 Billion1.93% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $156B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...